Cidara buys back rights to flu therapy from J&J for $85m
Cidara Therapeutics has entered into a definitive agreement with Johnson & Johnson (J&) to buy back the rights to its…
25 Apr 2024
Mundipharma to acquire rezafungin assets from Cidara Therapeutics
Mundipharma has signed an agreement to acquire all assets and rights related to antifungal candidate Rezzayo (rezafungin) from Cidara Therapeutics, including ongoing development and distribution. The assets and rights will…
24 Apr 2024
Incyte signs deal to acquire Escient Pharmaceuticals
Incyte has agreed to acquire US-based Escient Pharmaceuticals and its assets, including two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast…
12 Apr 2024
Century secures $60m in stock sale and buys preclinical cell therapy biotech
Century Therapeutics has acquired US-based Clade Therapeutics, which specialises in allogeneic cell therapies, to expand its pipeline of cancer and autoimmune therapies. For the acquisition, Century will pay an upfront…
12 Apr 2024
Eliem Therapeutics agrees to acquire Tenet
US-based Eliem Therapeutics has announced a definitive agreement for the acquisition of development-stage private biotechnology company Tenet Medicines. The acquisition is aimed at enhancing Eliem’s portfolio with a clinical-stage programme…
04 Apr 2024
Kintara and TuHURA enter merger deal to advance oncology pipeline
Kintara Therapeutics has signed a definitive agreement to execute an all-stock merger with TuHURA Biosciences to form a company for developing late-stage oncology assets. The merged entity, set to operate…
03 Apr 2024
Aditxt to acquire Appili Therapeutics
Aditxt has announced a definitive agreement under which its subsidiary, Adivir, will acquire complete issued and outstanding Class A common shares of biopharmaceutical company Appili Therapeutics. The move enhances Aditxt's…